Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cells, Cultured
Curcuma
/ chemistry
Curcumin
/ administration & dosage
Drug Carriers
/ adverse effects
Drug Compounding
/ methods
Drug Delivery Systems
/ adverse effects
Drug Liberation
Drug Synergism
Humans
Influenza A Virus, H1N1 Subtype
/ chemistry
Materials Testing
Nanoparticles
/ administration & dosage
Virosomes
/ adverse effects
Virus Inactivation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
received:
27
07
2020
accepted:
02
12
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
1
9
2021
Statut:
epublish
Résumé
The present study represents a formulation of nanocurcumin based hybrid virosomes (NC-virosome) to deliver drugs at targeted sites. Curcumin is a bioactive component derived from Curcuma longa and well-known for its medicinal property, but it exhibits poor solubility and rapid metabolism, which led to low bioavailability and hence limits its applications. Nanocurcumin was prepared to increase the aqueous solubility and to overcome all the limitations associated with curcumin. Influenza virosomes were prepared by solubilization of the viral membrane with 1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC). During membrane reconstitution, the hydrophilic nanocurcumin was added to the solvent system, followed by overnight dialysis to obtain NC-virosomes. The same was characterized using a transmission electron microscope (TEM) and scanning electron microscope (SEM), MTT assay was used to evaluate it's in vitro-cytotoxicity using MDA-MB231 and Mesenchyme stem cells (MSCs). The results showed NC-virosomes has spherical morphology with size ranging between 60 and 90 nm. It showed 82.6% drug encapsulation efficiency. The viability of MDA-MB231 cells was significantly inhibited by NC-virosome in a concentration-dependent manner at a specific time. The IC50 for nanocurcumin and NC-virosome was 79.49 and 54.23 µg/ml, respectively. The site-specific drug-targeting, high efficacy and non- toxicity of NC-virosomes proves its future potential as drug delivery vehicles.
Identifiants
pubmed: 33432002
doi: 10.1038/s41598-020-79631-1
pii: 10.1038/s41598-020-79631-1
pmc: PMC7801424
doi:
Substances chimiques
Drug Carriers
0
Virosomes
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
368Références
Int J Biol Macromol. 2017 May;98:366-378
pubmed: 28167107
Colloids Surf B Biointerfaces. 2018 Dec 1;172:51-59
pubmed: 30134219
Nutr Cancer. 2014;66(6):1015-22
pubmed: 25068616
Acta Trop. 1993 Dec;55(4):257-61
pubmed: 8147282
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
J Liposome Res. 2007;17(3-4):197-203
pubmed: 18027240
Clin Cancer Res. 2004 Apr 1;10(7):2530-7
pubmed: 15073133
Biomed Res Int. 2015;2015:824746
pubmed: 25793208
Breast Cancer Res. 2009;11(4):R43
pubmed: 19575785
Drug Dev Res. 2017 Sep;78(6):283-291
pubmed: 28815721
J Control Release. 2001 Jul 6;74(1-3):47-61
pubmed: 11489482
Acc Chem Res. 2000 Feb;33(2):94-101
pubmed: 10673317
Acta Pharm. 2015 Jun;65(2):105-16
pubmed: 26011928
EMBO J. 1986 Dec 20;5(13):3429-35
pubmed: 3030726
Vaccine. 2003 Feb 14;21(9-10):925-31
pubmed: 12547604
J Nanosci Nanotechnol. 2004 May;4(5):471-83
pubmed: 15503432
J Nucl Med. 2010 Aug;51(8):1167-70
pubmed: 20660380
J Cell Biol. 1981 Jun;89(3):674-9
pubmed: 6265470
J Ethnopharmacol. 2005 Aug 22;100(1-2):72-9
pubmed: 16009521
J Microencapsul. 1997 Jan-Feb;14(1):79-90
pubmed: 8994077
Nanomaterials (Basel). 2018 Jan 04;8(1):
pubmed: 29300349
Oncotarget. 2017 Jul 11;8(39):66680-66698
pubmed: 29029547
J Control Release. 2012 Sep 10;162(2):400-6
pubmed: 22759980
Cell. 1985 Mar;40(3):627-33
pubmed: 3882238
Microsc Res Tech. 2005 Sep;68(1):51-8
pubmed: 16208719
J Agric Food Chem. 2011 Mar 9;59(5):2056-61
pubmed: 21322563
Eur J Pharm Biopharm. 2015 Aug;94:251-63
pubmed: 26047796
FEBS Lett. 2002 Mar 27;515(1-3):184-8
pubmed: 11943218
Avicenna J Phytomed. 2016 Jul-Aug;6(4):383-98
pubmed: 27516979